📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Case Studies
Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates
UK-based small molecule drug discovery company Focus on identifying novel treatments of inflammatory respiratory diseases,…
Journal Papers
Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist
Earl Clarke, Christopher I Jarvis, Maria B Goncalves, …
News
Sygnature Discovery’s Head Quarters is nominated for RICS Awards 2018
On the 26th of February 2018, in Nottingham, UK, an esteemed milestone was reached as…
Technical Notes
Caco-2 Permeability
The human colon epithelial cancer cell line, Caco-2, is used as a model of human intestinal absorption of drugs. This model is suitable to test compound suitability for oral dosing, predict intestinal permeability and investigate drug efflux.
Technical Notes
Chemical Stability
Explore drug stability assessment under physiological conditions using Sygnature's chemical stability assay. Learn about its significance in understanding molecule lability and potential impacts on biological data and pharmacokinetics.
Technical Notes
P450 / CYP Inhibition
Discover P450/CYP inhibition & drug interactions. Assess CYP isoforms, predict co-administered drug risks. Reliable screening with Sygnature.
Technical Notes
Hepatocyte Metabolic Stability
The liver is the major site of drug metabolism in the body, with well over…
Technical Notes
Microsomal Clearance and Stability
Discover the significance of hepatic drug metabolism through microsomal clearance studies. Sygnature offers NADPH-based Phase I assays and combined Phase I/Phase II assays for comprehensive metabolism insights. Gain compound ranking and predict in vivo hepatic clearance. Validated with species-specific controls, get accurate mean intrinsic clearance and half-life measurements.
Technical Notes
Plasma Protein Binding
Streamlined Plasma Protein Binding Assessment Using Rapid Equilibrium Dialysis In drug development, understanding plasma protein…
Technical Notes
Plasma and Blood Stability
Improve in vivo PK studies by evaluating chemical stability in plasma. Our assay measures molecule stability in mouse, rat & human plasma, aiding compound prioritisation. Explore species differences. Proven positive & negative control compounds.
Case Studies
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Journal Papers
Correction: Conformationally restricted benzothienoazepine respiratory syncytial virus inhibitors: their synthesis, structural analysis and biological activities
Euan A F Fordyce, S Fraser Hunt, Damien Crepin, Stuart T Onions, Guillaume F Parra, Chris J Sleigh, John King-Underwood, Harry Finch, John…
Journal Papers
Combinatorial Biophysical Approach: FTSA and SPR for Small Molecule Ligand and PAIN Identification
Biophysical dual method: FTSA and SPR for drug discovery. Explore ligands and PAINs, gain insights on affinity values and compound binding.
Journal Papers
1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as potent GR antagonists with reduced hERG inhibition and an improved pharmacokinetic profile
Hunt, H. J., Belanoff, J.K., Golding, E., Gourdet, B., Phillips, T., Swift, D., Thomas, J., Unitt,…
Journal Papers
The Identification of the Clinical Candidate
The Identification of the Clinical Candidate (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1Hpyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134):– A Selective Glucocorticoid Receptor (GR) Antagonist Hunt,…
Journal Papers
Thermal Shift as an Entropy Driven Effect
Redhead M, Satchell R, McCarthy C, Pollack S, Unitt J. Biochemistry. 2017 Nov 28;56(47):6187-6199 Abstract…
Journal Papers
Surface Plasmon Resonance for Small Molecule Ligand Analysis
From the book “Biophysical Techniques in Drug Discovery”, Chapter 7, Pages 170 – 207 Editor: Angeles…
Technical Notes
MDCK-WT/MDR1 Permeability
Wild-type MDCK (Madin-Darby canine kidney) cells, when transfected with either the Multidrug Resistance gene-1 (MDR1;…
Technical Notes
Time Dependent Inhibition
Explore Time-Dependent Inhibition (TDI) & Drug Interactions with Sygnature's CYP450 Assay. Predict IC50 Shift & Enzyme Dynamics.
Technical Notes
Parallel Artificial Membrane Permeability Assay (PAMPA)
Enhance drug development using PAMPA assay for permeability assessment. Rapid, accurate, and high-throughput method. Sygnature's advanced approach with Corning's pre-coated plate system. LC-MS/MS readouts and precise calibration curve ensure reliable results. Caffeine and Famotidine controls included.
Journal Papers
FKBP5 mRNA Expression is a Biomarker for GR Antagonism
Developing a qPCR assay to monitor mifepristone's effectiveness in Cushing's syndrome patients.
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch